Registro:

Referencias:

• Soldin, O.P., Chung, S.H., Mattison, D.R., Sex differences in drug disposition (2011) J Biomed Biotechnol, 2011, p. 187103
• Soldin, O.P., Mattison, D.R., Sex differences in pharmacokinetics and pharmacodynamics (2009) Clin Pharmacokinet, 48, pp. 143-157
• Arafah, B.M., Nasrallah, M.P., Pituitary tumors: Pathophysiology, clinical manifestations and management (2001) Endocr Relat Cancer, 8, pp. 287-305
• Ben-Jonathan, N., Hnasko, R., Dopamine as a prolactin (PRL) inhibitor (2001) Endocr Rev, 22, pp. 724-763
• Ben-Jonathan, N., Dopamine: A prolactin-inhibiting hormone (1985) Endocr Rev, 6, pp. 564-589
• Missale, C., Nash, S.R., Robinson, S.W., Jaber, M., Caron, M.G., Dopamine receptors: From structure to function (1998) Physiol Rev, 78, pp. 189-225
• Freeman, M.E., Kanyicska, B., Lerant, A., Nagy, G., Prolactin: Structure, function, and regulation of secretion (2000) Physiol Rev, 80, pp. 1523-1631
• Díaz-Torga, G., Feierstein, C., Libertun, C., Disruption of the D2 dopamine receptor altersGHand IGF-I secretion and causes dwarfism in male mice (2002) Endocrinology, 143, pp. 1270-1279
• Kelly, M.A., Rubinstein, M., Asa, S.L., Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptordeficient mice (1997) Neuron, 19, pp. 103-113
• Saiardi, A., Bozzi, Y., Baik, J.H., Borrelli, E., Antiproliferative role of dopamine: Loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia (1997) Neuron, 19, pp. 115-126
• Asa, S.L., Kelly, M.A., Grandy, D.K., Low, M.J., Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice (1999) Endocrinology, 140, pp. 5348-5355
• Sarkar, D.K., Kim, K.H., Minami, S., Transforming growth factor-β1 messenger RNA and protein expression in the pituitary gland: Its action on prolactin secretion and lactotropic growth (1992) Mol Endocrinol, 6, pp. 1825-1833
• Sarkar, D.K., Pastorcic, M., De A Engel, M., Moses, H., Ghasemzadeh, M.B., Role of transforming growth factor-β type i and TGF-β type II receptors in the TGF-β1-regulated gene expression in pituitary prolactin- secreting lactotropes (1998) Endocrinology, 139, pp. 3620-3628
• Recouvreux, M.V., Guida, M.C., Rifkin, D.B., Becu-Villalobos, D., Díaz-Torga, G., Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary (2011) Endocrinology, 152, pp. 2722-2730
• Pastorcic, M., De A Boyadjieva, N., Vale, W., Sarkar, D.K., Reduction in the expression and action of transforming growth factor-β1 on lactotropes during estrogen-induced tumorigenesis (1995) Cancer Res, 55, pp. 4892-4898
• Sarkar, D.K., Chaturvedi, K., Oomizu, S., Boyadjieva, N.I., Chen, C.P., Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-β1, and TGF-β type II receptor interact to inhibit the growth of pituitary lactotropes (2005) Endocrinology, 146, pp. 4179-4188
• De A Morgan, T.E., Speth, R.C., Boyadjieva, N., Pastorcic, M., Sarkar, D.K., Pituitary lactotrope expresses transforming growth factor β (TGF-β) type II receptormRNAand protein and contains I-TGF-β1 binding sites (1995) J Endocrinol, 149, pp. 19-27
• Annes, J.P., Munger, J.S., Rifkin, D.B., Making sense of latent TGFβ activation (2003) J Cell Sci, 116, pp. 217-224
• Rifkin, D.B., Latent transforming growth factor-β (TGF-β) binding proteins: Orchestrators of TGF-β availability (2005) J Biol Chem, 280, pp. 7409-7412
• Annes, J.P., Chen, Y., Munger, J.S., Rifkin, D.B., Integrin αvβ6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1 (2004) J Cell Biol, 165, pp. 723-734
• Yoshinaga, K., Obata, H., Jurukovski, V., Perturbation of transforming growth factor (TGF)-β1 association with latent TGF-β binding protein yields inflammation and tumors (2008) Proc Natl Acad Sci USA, 105, pp. 18758-18763
• Recouvreux, M.V., Camilletti, M.A., Rifkin, D.B., Becu-Villalobos, D., Díaz-Torga, G., Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1) (2012) Endocrinology, 153, pp. 3861-3871
• Gudelsky, G.A., Porter, J.C., Sex-related difference in the release of dopamine into hypophysial portal blood (1981) Endocrinology, 109, pp. 1394-1398
• Brunschwig, E.B., Wilson, K., Mack, D., PMEPA1, a transforming growth factor-β-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer (2003) Cancer Res, 63, pp. 1568-1575
• Levy, L., Hill, C.S., Smad4 dependency defines 2 classes of transforming growth factor β (TGF-β) target genes and distinguishes TGF-β-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses (2005) Mol Cell Biol, 25, pp. 8108-8125
• Dennler, S., Itoh, S., Vivien, D., Ten Dijke, P., Huet, S., Gauthier, J.M., Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene (1998) EMBO J, 17, pp. 3091-3100
• Day, R., Schafer, M.K., Watson, S.J., Chrétien, M., Seidah, N.G., Distribution and regulation of the prohormone convertases PC1 and PC2 in the rat pituitary (1992) Mol Endocrinol, 6, pp. 485-497
• Strongin, A.Y., Collier, I., Bannikov, G., Marmer, B.L., Grant, G.A., Goldberg, G.I., Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease (1995) J Biol Chem, 270, pp. 5331-5338
• Butler, G.S., Butler, M.J., Atkinson, S.J., The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study (1998) J Biol Chem, 273, pp. 871-880
• Mu, D., Cambier, S., Fjellbirkeland, L., The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1 (2002) J Cell Biol, 157, pp. 493-507
• Munger, J.S., Huang, X., Kawakatsu, H., The integrin αvβ6 binds and activates latentTGFβ 1: A mechanism for regulating pulmonary inflammation and fibrosis (1999) Cell, 96, pp. 319-328
• Annes, J.P., Rifkin, D.B., Munger, J.S., The integrin αvβ6 binds and activates latent TGFβ3 (2002) FEBS Lett, 511, pp. 65-68
• Hatala, M.A., Powers, C.A., Development of the sex difference in glandular kallikrein and prolactin levels in the anterior pituitary of the rat (1988) Biol Reprod, 38, pp. 846-852
• Kizuki, K., Kitagawa, A., Takahashi, M., Moriya, H., Kudo, M., Noguchi, T., Immunohistochemical localization of kallikrein within the prolactin- producing cells of the rat anterior pituitary gland (1990) J Endocrinol, 127, pp. 317-323
• Kitagawa, A., Kizuki, K., Moriya, H., Kudo, M., Noguchi, T., Kallikreinand prolactin-producing cells in the rat anterior pituitary are the same (1990) J Biochem, 108, pp. 971-975
• Pritchett, D.B., Roberts, J.L., Dopamine regulates expression of the glandular-type kallikrein gene at the transcriptional level in the pituitary (1987) Proc Natl Acad Sci USA, 84, pp. 5545-5549
• Mohankumar, S.M., Kasturi, B.S., Shin, A.C., Chronic estradiol exposure induces oxidative stress in the hypothalamus to decrease hypothalamic dopamine and cause hyperprolactinemia (2011) Am J Physiol Regul Integr Comp Physiol, 300, pp. R693-R699
• Csakvari, E., Kurunczi, A., Hoyk, Z., Gyenes, A., Naftolin, F., Parducz, A., Estradiol-induced synaptic remodeling of tyrosine hydroxylase immunopositive neurons in the rat arcuate nucleus (2008) Endocrinology, 149, pp. 4137-4141
• Weikkolainen, K., Keski-Oja, J., Koli, K., Expression of latent TGF-β binding protein LTBP-1 is hormonally regulated in normal and transformed human lung fibroblasts (2003) Growth Factors, 21, pp. 51-60
• Taipale, J., Saharinen, J., Hedman, K., Keski-Oja, J., Latent transforming growth factor-β1 and its binding protein are components of extracellular matrix microfibrils (1996) J Histochem Cytochem, 44, pp. 875-889
• Koski, C., Saharinen, J., Keski-Oja, J., Independent promoters regulate the expression of two amino terminally distinct forms of latent transforming growth factor-beta binding protein-1 (LTBP-1) in a cell type-specific manner (1999) J Biol Chem, 274, pp. 32619-32630
• Sarkar, A.J., Chaturvedi, K., Chen, C.P., Sarkar, D.K., Changes in thrombospondin- 1 levels in the endothelial cells of the anterior pituitary during estrogen-induced prolactin-secreting pituitary tumors (2007) J Endocrinol, 192, pp. 395-403
• Turner, H.E., Nagy, Z., Esiri, M.M., Harris, A.L., Wass, J.A., Role of matrix metalloproteinase 9 in pituitary tumor behavior (2000) J Clin Endocrinol Metab, 85, pp. 2931-2935
• Liu, W., Matsumoto, Y., Okada, M., Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas (2005) J Med Invest, 52, pp. 151-158
• Gong, J., Zhao, Y., Abdel-Fattah, R., Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas (2008) Pituitary, 11, pp. 37-48
• Murphy-Ullrich, J.E., Poczatek, M., Activation of latent TGF-β by thrombospondin-1: Mechanisms and physiology (2000) Cytokine Growth Factor Rev, 11, pp. 59-69
• Emami, N., Diamandis, E.P., Potential role of multiple members of the kallikrein-related peptidase family of serine proteases in activating latent TGFβ1 in semen (2010) Biol Chem, 391, pp. 85-95
• Akita, K., Okuno, M., Enya, M., Impaired liver regeneration in mice by lipopolysaccharide via TNF-α/kallikrein-mediated activation of latent TGF-β (2002) Gastroenterology, 123, pp. 352-364

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------